Archives
-
SIRT1/2 Inhibitor IV: Assay Logic Beyond IC50
2026-08-24
SIRT1/2 Inhibitor IV (cambinol) is a cell-permeable tool for separating SIRT1- and SIRT2-linked signaling from downstream acetylation and lactylation phenotypes. This guide translates recent Ran lactylation findings into evidence-aware assay design across CNS injury, cancer, hypoxia, and metabolic research.
-
Trichostatin A (TSA): Practical Lab Guide
2026-08-23
Trichostatin A (TSA), SKU A8183, provides a dossier-supported way to study reversible HDAC inhibition, histone acetylation, cell-cycle responses, and differentiation in experimental systems. It is suitable for controlled cell-based cancer research and epigenetic assays, but product concentrations, vehicle tolerance, and animal-model findings should not be treated as universal or clinical dosing guidance.
-
Mutant p53-R280K Reprograms Lipogenesis via FASN
2026-08-22
The reference study identifies a gain-of-function mechanism in which mutant p53-R280K co-opts SREBP1 to activate FASN transcription, increasing de novo fatty acid synthesis in breast cancer cells. Genetic and pharmacological evidence places FASN downstream of this pathway and links the p53-R280K/SREBP1/FASN axis to tumor growth and lung metastasis.
-
Vorinostat: Linking HDAC Inhibition to Cell Death
2026-08-22
Vorinostat and suberoylanilide hydroxamic acid are examined through a mechanistic framework that separates HDAC target engagement, transcriptional change, and cell death. This guide shows how the RNA Pol II degradation study can improve assay design and interpretation in cancer biology research.
-
BCECF for pH Readouts in Efferocytosis Models
2026-08-21
BCECF enables quantitative extracellular pH analysis in efferocytosis and neuropathic pain research. This article presents a practical framework for separating pH-associated phenotypes from AMPK/Gas6-MerTK/SOCS3 mechanism, with calibration, controls, and interpretation guidance.
-
Tubastatin A Limits Myocardial Injury After Resuscitation
2026-08-20
A 2025 porcine cardiac-arrest study examined whether Tubastatin A could reduce myocardial injury after cardiopulmonary resuscitation by suppressing GSDME-associated pyroptosis and MLKL-associated necroptosis. The findings connect HDAC6 inhibition with improved cardiac function, lower injury biomarkers, and reduced inflammatory cell-death signals, while remaining preliminary because the mechanism and clinical transferability were not fully established.
-
Trichostatin A (TSA): A Causal Assay Guide
2026-08-20
Trichostatin A (TSA) is a reversible HDAC inhibitor for dissecting histone acetylation, cell-cycle control, and cancer phenotypes. This guide pairs TSA biology with a causal, multi-assay strategy inspired by recent vascular cognitive impairment research.
-
Nerve-Driven HDAC1 in Axolotl Limb Regeneration
2026-08-19
The reference study identifies nerve-mediated HDAC1 up-regulation as a regulatory requirement for blastema formation and successful axolotl limb regeneration. By combining inhibitor treatment, denervation, time-course analysis, and nerve-factor supplementation, it connects neural signaling with epigenetic control at the wound epidermis.
-
Trichostatin A for Chromatin and Cell-State Studies
2026-08-19
Trichostatin A (TSA) provides a reversible way to perturb histone acetylation while connecting chromatin state to differentiation, proliferation, and cell-cycle phenotypes. This workflow translates a dynamic cardiomyocyte chromatin study into practical assay designs for cardiac maturation and cancer research, with clear controls for dose, timing, and solvent effects.
-
Tubastatin A: HDAC6 Inhibition in Research Workflows
2026-08-18
Tubastatin A is a selective HDAC6 inhibitor for connecting microtubule acetylation with cell stress, inflammation, and regulated cell death. This practical guide translates porcine post-resuscitation findings into assay design, dosing logic, controls, and troubleshooting strategies for translational research.
-
NAD+ Workflows for Energy-Stress Assays
2026-08-18
Build reproducible NAD+ assays that distinguish redox effects, cofactor activity, and autophagy signaling during energy stress. This workflow pairs NAD+ measurements with the AMPK–ULK1 insights of a recent reference study to prevent misleading interpretations.
-
NADH/NAD+ Redox Imbalance in Diabetic Kidney Disease
2026-08-17
This review frames NADH/NAD+ redox imbalance as a central link between deranged glucose metabolism, mitochondrial dysfunction, oxidative stress, and diabetic kidney disease. Its main practical contribution is an integrated map of NADH-generating and NAD+-depleting pathways, together with experimental considerations for evaluating mitochondrial injury and redox-restoring interventions.
-
O-GlcNAcylation Rewires Glycolysis in Bone Formation
2026-08-17
The reference study shows that Wnt3a promotes osteoblastogenesis by increasing O-GlcNAcylation through both rapid Ca2+-PKA-GFAT1 signaling and prolonged Wnt-β-catenin activity. Mechanistically, O-GlcNAc modification of PDK1 stabilizes this glycolytic regulator, linking glucose metabolism to bone formation and fracture repair.
-
Medroxyprogesterone acetate in Decidualization Research
2026-08-16
Medroxyprogesterone acetate enables controlled interrogation of progesterone-receptor and glucocorticoid-receptor signaling across reproductive, renal, and neurobiology models. This workflow shows how to prepare MPA, select exposure conditions, connect it to vitamin D/VDR decidualization assays, and troubleshoot hormone-response experiments.
-
Panobinostat (LBH589): From Acetylation to Apoptosis
2026-08-15
Panobinostat (LBH589) offers translational researchers a way to connect broad HDAC inhibition with chromatin remodeling, apoptotic signaling, and drug-resistance biology. This thought-leadership analysis places the compound alongside emerging evidence that RNA polymerase II loss can actively signal cell death, while defining practical assay strategies and the limits of mechanistic interpretation.